Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 04 - 13 tags : Phase 3 save search
Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics’ Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy
Published: 2021-04-13 (Crawled : 00:00) - globenewswire.com
GALT | $3.365 9.97% 9.06% 240K
|
Health Technology
|
| O: 31.87%
H: 0.18%
C: -17.34%
immunotherapy phase 1 therapy cancer research phase 2 phase 3 galectin-3
Endo Announces Publication of Phase 3 Qwo® (collagenase clostridium histolyticum-aaes) Data in Peer-Reviewed Dermatologic Surgery
Published: 2021-04-13 (Crawled : 21:00) - prnewswire.com
ENDP | News | $0.2926 -9.6%
|
Health Technology
|
| O: -0.16%
H: 5.57%
C: 2.79%
phase 3
Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction
Published: 2021-04-13 (Crawled : 13:00) - biospace.com/
BHC | $8.53 0.95% 0.0% 4M
|
Health Technology
|
| O: 0.03%
H: 0.17%
C: -0.5%
dry eye disease eye eye disease results topline phase 3 trial
Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
Published: 2021-04-13 (Crawled : 12:00) - biospace.com/
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: 50.14%
H: 10.14%
C: -0.34%
lung cancer cancer phase 3 trial dmc recommendations decades
Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis
Published: 2021-04-13 (Crawled : 12:00) - biospace.com/
GERN | $3.495 -6.3% -6.72% 10M
|
Health Technology
|
| O: -0.7%
H: 2.13%
C: 1.42%
fibrosis phase 3 trial
Zai Lab Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
Published: 2021-04-13 (Crawled : 12:00) - globenewswire.com
ZLAB | $15.13 0.93% 0.93% 470K
|
Health Technology
|
| O: 13.59%
H: 7.76%
C: 7.53%
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: 50.14%
H: 10.14%
C: -0.34%
lung cancer cancer phase 3 trial
Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021
Published: 2021-04-13 (Crawled : 01:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.35%
H: 1.36%
C: 0.75%
treatment lung cancer injection results cancer phase 3
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.